These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19195302)

  • 21. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
    Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
    Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].
    Colonna P; Abrignani MG; Colivicchi F; Verdecchia P; Alunni G; Bongo AS; Ceravolo R; Oliva F; Rakar S; Riccio C; Scherillo M; Valle R; Bovenzi F;
    G Ital Cardiol (Rome); 2013 Apr; 14(4):295-322. PubMed ID: 23567775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke prevention in atrial fibrillation.
    Verheugt FW
    Neth J Med; 2006 Feb; 64(2):31-3. PubMed ID: 16517985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboembolic and haemorrhagic events in permanent atrial fibrillation: observational study in an emergency department.
    Rovellini A; Folli C; Cardani F; Monzani V
    Eur J Intern Med; 2009 Dec; 20(8):756-9. PubMed ID: 19892303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of thromboembolic complications in patients with atrial fibrillation.
    Spiezia L; Prandoni P
    Minerva Cardioangiol; 2008 Dec; 56(6):643-52. PubMed ID: 19092739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
    Lang NN; Connelly DT
    J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of atrial fibrillation in dialyzed patients: the role of oral anticoagulants. The cardiologist's point of view].
    Lucreziotti S; Lombardi F
    G Ital Nefrol; 2010; 27(3):222-9. PubMed ID: 20540014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risk stratification in atrial and ventricular arrhythmias].
    Fauchier L; Robin I; de Labriolle A; Poret P; Giraudeau C; Cosnay P; Babuty D
    Ann Cardiol Angeiol (Paris); 2006 Jun; 55(3):127-34. PubMed ID: 16792027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
    Hylek EM; Evans-Molina C; Shea C; Henault LE; Regan S
    Circulation; 2007 May; 115(21):2689-96. PubMed ID: 17515465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention.
    Thomson R; Eccles M; Wood R; Chinn DJ
    Med Decis Making; 2007; 27(4):438-47. PubMed ID: 17641140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention of thromboembolism in patients with atrial fibrillation].
    Veselka J; Bartůnĕk P
    Vnitr Lek; 1996 Nov; 42(11):792-5. PubMed ID: 9012126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of atrial fibrillation in dialyzed patients: the role of oral anticoagulants. The nephrologist's point of view].
    Scanziani R; Galassi A
    G Ital Nefrol; 2010; 27(3):230-6. PubMed ID: 20540015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevention of thromboembolism in atrial fibrillation].
    Aguiar C
    Rev Port Cardiol; 2012 Apr; 31 Suppl 1():17-26. PubMed ID: 22541031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of thromboembolism in atrial fibrillation of non-valvular etiology].
    Cattaneo M
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():15S-17S. PubMed ID: 9004815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thromboembolic risk].
    Abrignani MG; Colivicchi F
    Monaldi Arch Chest Dis; 2013 Jun; 80(2):60-5. PubMed ID: 24494408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stroke risk stratification in atrial fibrillation: oral anticoagulant therapy and bleeding risk in the elderly].
    Poli D; Grifoni E
    Recenti Prog Med; 2011 Jan; 102(1):23-7. PubMed ID: 21516668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thromboembolic and bleeding risk assessment in patients with non-rheumatic atrial fibrillation using CHA2DS2-VASc and HAS-BLED scoring systems].
    Bozić I; Cvitković I; Carević V; Caljkusić K; Trgo G; Fabijanić D
    Lijec Vjesn; 2013; 135(3-4):86-91. PubMed ID: 23671975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stroke prevention in atrial fibrillation--pharmacologic strategies.
    Tiyyagura SR; Goldbarg SH; Mehta D
    Indian Heart J; 2007; 59(4):311-5. PubMed ID: 19126935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
    Yameogo AR; Kologo JK; Mandi G; Kabore HP; Millogo GR; Seghda AA; Samadoulougou AK; Zabsonre P
    Pan Afr Med J; 2016; 24():108. PubMed ID: 27642447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.